Stay updated on Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The clinical trial record for tisotumab vedotin in platinum-resistant ovarian cancer is available again, with study details, participant criteria, outcomes, locations, and supporting documents.
    Difference
    78%
    Check dated 2026-11-09T12:56:20.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.2 to v3.8.0 while the page continued to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T12:37:52.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T15:25:31.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer now identifies ClinicalTrials.gov as revision v3.7.2 instead of v3.7.1, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T14:58:40.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page remains an access-denied error.
    Difference
    0.2%
    Check dated 2026-10-12T15:29:05.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error, preventing access to the study details and page content.
    Difference
    0.5%
    Check dated 2026-09-28T18:03:07.000Z thumbnail image

Stay in the know with updates to Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Weekly Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer Clinical Trial page.